Johnson and Johnson's CAR-T therapy JNJ-4528 for multiple myeloma: 86% of patients receive full remission
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Johnson and Johnson released the latest results from its mid-stage trial of THE CAR-T cell therapy JNJ-4528, which showed a high response rate in patients with recurrent or refractory multiple myelomaAccording to the Ib/II phase of the study CARTITUDE-1, all patients responded to the therapy, with 86 percent of patients having complete remission in the 11.5-month median follow-up and 86 percent of patients withno progress in the 9th monththe company noted that the treatment achieved a 100% total response rate (ORR), with 97 percent of patients achieving good partial or higher results, and 3 percent of patients having partial remissionin addition, responses were observed in patients who had previously received multiple treatments (n-29), who received a previous treatment regimen with a median of five (ranges of 3-18)The median time for the first reaction after JNJ-4528 was one month, and 81% of patients achieved a minimum residual lesions (MRD) negative state at the first full responsethe most common adverse events observed in CARTITUDE-1 were neutroperatic granulocytic cell reduction (100%) and cytokine release syndrome (CRS, 93%), and neurotoxic syndrome (ICANS) associated with immune-effect cells was observed in three patients (10%)reported three deaths in the Phase Ib study: 1 due to CRS, 1 case due to acute myeloid leukemia (unrelated to treatment) and 1 case due to disease progression
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
